Lupin receives USFDA approval for Mycophenolic Acid Delayed-Release Tablets

Lupin announced the approval of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg.

Lupin's alliance partner Concord Biotech (Concord) has received an approval for Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Myfortic Delayed Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg (RLD: Myfortic) had an annual sales of approximately USD 174 million in the U.S. (IQVIA MAT Sept ember 2019).

Powered by Capital Market - Live News